Do genetic polymorphisms influence imatinib trough concentrations in patients with chronic myeloid leukemia? A systematic review and meta-analysis.
[INTRODUCTION] Chronic myeloid leukemia (CML) is effectively treated with tyrosine kinase inhibitors such as imatinib, though drug response varies among patients.
- 95% CI 208.06-391.62
- 연구 설계 meta-analysis
APA
de Moraes FCA, Matheus GTFU, et al. (2025). Do genetic polymorphisms influence imatinib trough concentrations in patients with chronic myeloid leukemia? A systematic review and meta-analysis.. Expert review of anticancer therapy, 1-10. https://doi.org/10.1080/14737140.2025.2602802
MLA
de Moraes FCA, et al.. "Do genetic polymorphisms influence imatinib trough concentrations in patients with chronic myeloid leukemia? A systematic review and meta-analysis.." Expert review of anticancer therapy, 2025, pp. 1-10.
PMID
41367289
Abstract
[INTRODUCTION] Chronic myeloid leukemia (CML) is effectively treated with tyrosine kinase inhibitors such as imatinib, though drug response varies among patients. Genetic polymorphisms in drug transporter genes ABCB1 and ABCG2 influence imatinib plasma trough concentrations (Ctrough).
[METHODS] Statistical analyses were performed using fixed-effect models and heterogeneity was assessed using I² statistic.
[RESULTS] This meta-analysis evaluated nine studies including 1,098 heterozygous patients, 519 variant carriers, and 896 wild-type individuals. Results showed significantly higher Ctrough in patients with the ABCB1 c.3435C>T TT genotype compared with CC with data of 7 studies (MD = 299.84; 95% CI: 208.06-391.62; = 0.0097; I² = 77%). Similarly, ABCB1 c.2677G>T GT (MD = 327.62; 95% CI: 198.90-456.34; = 0.0008; I² = 52%) and TT (MD = 289.22; 95% CI: 135.63-442.81; < 0.001; I² = 12%) genotypes were associated with higher levels than GG, both assessed by 4 studies. Additionally, data from 5 studies observed that ABCG2 c.412C>A CA carriers had increased Ctrough versus CC (MD = 186.83; 95% CI: 67.11-306.56; = 0.022; I² = 32%).
[CONCLUSIONS] These findings support the role of pharmacogenetic screening in optimizing imatinib therapy, improving efficacy, and reducing risks of adverse outcomes.
[REGISTRATION] PROSPERO (CRD42024574179).
[METHODS] Statistical analyses were performed using fixed-effect models and heterogeneity was assessed using I² statistic.
[RESULTS] This meta-analysis evaluated nine studies including 1,098 heterozygous patients, 519 variant carriers, and 896 wild-type individuals. Results showed significantly higher Ctrough in patients with the ABCB1 c.3435C>T TT genotype compared with CC with data of 7 studies (MD = 299.84; 95% CI: 208.06-391.62; = 0.0097; I² = 77%). Similarly, ABCB1 c.2677G>T GT (MD = 327.62; 95% CI: 198.90-456.34; = 0.0008; I² = 52%) and TT (MD = 289.22; 95% CI: 135.63-442.81; < 0.001; I² = 12%) genotypes were associated with higher levels than GG, both assessed by 4 studies. Additionally, data from 5 studies observed that ABCG2 c.412C>A CA carriers had increased Ctrough versus CC (MD = 186.83; 95% CI: 67.11-306.56; = 0.022; I² = 32%).
[CONCLUSIONS] These findings support the role of pharmacogenetic screening in optimizing imatinib therapy, improving efficacy, and reducing risks of adverse outcomes.
[REGISTRATION] PROSPERO (CRD42024574179).
같은 제1저자의 인용 많은 논문 (5)
- Leukotriene receptor antagonist drugs as potential chemopreventive agents: A systematic review and meta-analysis of cancer risk in asthmatic patients.
- Concomitant use of H1 antihistamines improves survival outcomes in cancer patients on immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
- Does Epstein-Barr Virus Contribute to Breast Cancer Risk Worldwide? A Systematic Review and Meta-Analysis.
- Vitamin K2 Supplementation and Clinical Outcomes in Hepatocellular Carcinoma Patients: A Meta-Analysis with Trial Sequential Analysis.
- Gastric cancer burden and regional disparities among Helicobacter pylori-positive patients in the Americas: a systematic review and meta-analysis.